News

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Jamie Dimon’s Tariffs Warning Should Have Rocked Markets. Why He’s Being Ignored.
Fed officials say debt downgrade complicates inflation outlook, Nvidia CEO discusses China chip ban, JPMorgan’s investor day, ...
Regeneron to buy bankrupt 23andMe for $256 million
Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...
Biotechnology company Regeneron buying 23andMe for $256 million
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron develops new medicines and it rang up $3.7 billion in sales for its anti-inflammatory drug Dupixent as a treatment for eczema, asthma and chronic obstructive pulmonary disease, in its latest ...
BioSpace2d
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...
Regeneron Upgraded as AbbVie Catches Policy Heat
With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...
Regeneron upgraded, AbbVie downgraded as Citi reviews policy risk
Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.